These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 38316378)
1. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer. Dunne EG; Fick CN; Isbell JM; Chaft JE; Altorki N; Park BJ; Spicer J; Forde PM; Gomez D; Iyengar P; Harpole DH; Stinchcombe TE; Liberman M; Bott MJ; Adusumilli PS; Huang J; Rocco G; Jones DR Ann Thorac Surg; 2024 Jul; 118(1):119-129. PubMed ID: 38316378 [TBL] [Abstract][Full Text] [Related]
2. The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis. Wu Y; Hu L; Zhang S; Zhang H Technol Cancer Res Treat; 2024; 23():15330338241258164. PubMed ID: 38872482 [No Abstract] [Full Text] [Related]
3. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review. Cui S; Wang N; Liang Y; Meng Y; Shu X; Kong F Int Immunopharmacol; 2024 Nov; 141():112903. PubMed ID: 39146783 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials. Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L Front Immunol; 2024; 15():1359302. PubMed ID: 38646542 [TBL] [Abstract][Full Text] [Related]
5. Top advances of the year: Perioperative therapy for lung cancer. Aredo JV; Wakelee HA Cancer; 2024 Sep; 130(17):2897-2903. PubMed ID: 38717993 [TBL] [Abstract][Full Text] [Related]
6. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review. Christopoulos P Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058 [TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives. Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393 [TBL] [Abstract][Full Text] [Related]
9. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer. Liu X; Xing H; Liu H; Chen J Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis. Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524 [TBL] [Abstract][Full Text] [Related]
11. [Comparison of Short-term Efficacy of Neoadjuvant Immunotherapy Combined with Chemotherapy and Surgery Alone for Locally Advanced Resectable Non-small Cell Lung Cancer]. Li H; Liu Q; Li B; Chen Y; Lin J; Meng Y; Feng H; Zheng Z; Hui Y Zhongguo Fei Ai Za Zhi; 2024 Jun; 27(6):421-430. PubMed ID: 39026493 [TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review. Zhao Z; Gao Y; Xue Q; Gao S; He J Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556 [TBL] [Abstract][Full Text] [Related]
13. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer. Lee JM; Tsuboi M; Brunelli A Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672 [TBL] [Abstract][Full Text] [Related]
14. Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review. West HJ; Kim JY JAMA Oncol; 2024 Feb; 10(2):249-255. PubMed ID: 38153722 [TBL] [Abstract][Full Text] [Related]
15. The role of immunotherapy in early-stage and metastatic NSCLC. Lieber A; Makai A; Orosz Z; Kardos T; Isaac SJ; Tornyi I; Bittner N Pathol Oncol Res; 2024; 30():1611713. PubMed ID: 39027681 [TBL] [Abstract][Full Text] [Related]
16. Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges. D'Aiello A; Stiles B; Ohri N; Levy B; Cohen P; Halmos B Clin Lung Cancer; 2024 May; 25(3):197-214. PubMed ID: 38462413 [TBL] [Abstract][Full Text] [Related]
17. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-small Cell Lung Cancer]. Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062 [TBL] [Abstract][Full Text] [Related]
18. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial. Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284 [TBL] [Abstract][Full Text] [Related]